Longitude Capital is a Menlo Park-based healthcare investment firm focused on growth-stage biotech, medtech, and health solutions. It targets companies that are already clinically de-risked or moving toward commercialization, rather than very early technical exploration. This makes it much more of a later-stage healthcare growth investor than a seed-stage neurotech backer.

Its neurotech portfolio includes Ceribell and Nalu Medical, both of which reflect a preference for companies with strong clinical evidence, regulatory progress, and near-term commercial readiness. Longitude’s investment style is centered on validated products and clear regulatory pathways rather than speculative frontier science. That makes it especially relevant for neurodevice businesses that have already passed key clinical or technical inflection points.

The firm invests primarily in the United States, with broader global awareness. For neurotech founders, Longitude is most relevant once a company has progressed through early validation and is approaching meaningful commercialization or scale-up. It is a strong fit for later-stage neurodevice and diagnostics companies rather than pre-seed neuroengineering ventures.